Infant Bacterial Therapeutics

Board/Management Information • May 20, 2021

Press Release May 20, 2021

Infant Bacterial Therapeutics CFO leaves the company

Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be acting CFO when Daniel leaves the company and until his replacement is in place. The recruitment process has already been initiated.

"I would like to take this opportunity to thank Daniel and wish him every success in the future", says Staffan Strömberg, Chief Executive Officer of IBT.

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in Phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis ("NEC") and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Infant Bacterial Therapeutics AB ("IBT") is a public company domiciled in Stockholm. The company's class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

For additional information please contact

Staffan Strömberg, CEO Daniel Mackey, CFO Infant Bacterial Therapeutics AB Bryggargatan 10 111 21 Stockholm Phone: +46 70 670 1226 info@ibtherapeutics.com www.ibtherapeutics.com

Publication

The information was submitted for publication, through the agency of the contact persons set out above, at 16:30 CET on May 20, 2021.